| Autor: |
S, Wassel, E, Tsompanidi, E, Tahmaz, B, Hörster, R, Hoerster |
| Jazyk: |
němčina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 116(5) |
| ISSN: |
1433-0423 |
| Popis: |
The clinical outcome of neovascular age-related macular degeneration (nAMD) depends on constant follow-up and consistent treatment. Data about the long-term course of intensive anti-vascular endothelial growth factor (VEGF) therapy from outpatient clinics are rare.The aim of the study was to characterize a population of nAMD patients with long-term follow-up and intensive anti-VEGF therapy.In a supra-regional outpatient clinic, we retrospectively identified patients who had received at least 30 intravitreal anti-VEGF injections and were followed for at least 4 years. All patients received an optical coherence tomography(OCT)-controlled Pro-Re-Nata (PRN) therapy regimen according to German guidelines.We identified 43 patients. Visual acuity at baseline was 0.44 ± 0.24 (1.0-0.1) logMAR. At the end of the follow-up period, visual acuity was 0.63 ± 3.6 (1.3-0.1) logMAR. Patients received a mean of 36.3 ± 8.0 (30-62) injections and were followed for a mean of 6.1 ± 1.8 (4-12) years. They received 6.12 ± 1.5 (3.1-9.9) injections per year. The number of injections in treatment-year one was with 3.67 ± 1.9 (1-8) significantly lower than the mean (p 0.0001).Despite intensive PRN therapy, visual acuity slowly decreased over time. The mean number of injections was comparable to that of prospective studies. The low number of injections in treatment-year 1 may have been due to a lack of experience with the new treatment agents. The slow decrease in visual acuity in clinical routine as opposed to clinical studies may be attributed to a delay between occurrence of disease activity and treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink